论文部分内容阅读
目的分析美罗华联合化疗在B细胞非霍奇金淋巴瘤治疗中的临床疗效。方法回顾40例B细胞非霍奇金淋巴瘤患者,采取美罗华静脉滴注治疗,同时联合相关化疗,分析患者治疗效果,并评价其安全性。结果 40例患者均顺利完成治疗疗程,治疗总有效率为95%,最长缓解时间到现在仍未复发,期间1例复发者经治疗后缓解,8个月再次复发,无法耐受继续化疗而死亡。静脉滴注美罗华期间,无肝肾功能损害、心电图改变等严重不良反应,不良反应仅为Ⅰ~Ⅱ级,表现为恶心呕吐,18例骨髓抑制,未影响治疗,经相应处理后好转。结论美罗华联合化疗治疗B细胞非霍奇金淋巴瘤取得效果显著,安全性高,值得临床推广应用。
Objective To analyze the clinical efficacy of rituximab in the treatment of B cell non-Hodgkin’s lymphoma. Methods Forty patients with B-cell non-Hodgkin’s lymphoma were retrospectively treated with intravenous infusion of rituximab, combined with chemotherapy, the therapeutic effect was analyzed and the safety was evaluated. Results All the 40 patients completed the course of treatment successfully. The total effective rate was 95%. The longest remission time did not recur till now. During the course of treatment, one patient relapsed after treatment and relapsed again after 8 months, and could not tolerate continuous chemotherapy death. Rituximab during intravenous administration, no liver and kidney dysfunction, ECG changes and other serious adverse reactions, adverse reactions are only Ⅰ ~ Ⅱ grade, showed nausea and vomiting, 18 cases of bone marrow suppression, did not affect the treatment, after appropriate treatment improved. Conclusion The combination of rituximab and chemotherapy in the treatment of B cell non-Hodgkin’s lymphoma has achieved remarkable results, which is safe and worthy of clinical application.